PEG-MGF: Mechano Growth Factor and the IGF-1Ec E-Domain — A 2026 Research Guide

Most peptides in the growth-hormone axis are studied as signals that arrive from somewhere else — released by the pituitary, carried in circulation, and read by a distant tissue. Mechano growth factor is studied as the opposite case: a locally produced fragment that appears in muscle only after the tissue has been mechanically loaded or damaged. It is not a separate gene product. It is what happens when the IGF-1 gene is spliced differently under mechanical stress, and the resulting C-terminal E-domain is cleaved away from the mature IGF-1 sequence and studied on its own. PEG-MGF is that E-domain peptide with polyethylene glycol conjugated to it, a modification introduced specifically because the unmodified peptide is short-lived in solution. This guide covers the molecular profile, the pathway-level mechanism, and what the published preclinical literature actually establishes — including the studies that failed to reproduce the central finding.

The information below describes in-vitro and preclinical laboratory research only. It is not medical guidance, and none of the findings described here establish safety or efficacy in humans.

Section 1 — Molecular Profile

MGF is not a designed molecule. It is a naturally occurring splice product, which makes its nomenclature more layered than most research peptides.

The human IGF1 gene produces several transcripts through alternative splicing of the E-domain region of the pro-IGF-1 precursor: IGF-1Ea, IGF-1Eb, and IGF-1Ec. The IGF-1Ec transcript — the isoform associated with mechanical loading and tissue damage, and the one commonly labeled MGF — arises from inclusion of exon 5, which shifts the reading frame and produces a distinct C-terminal extension. When the pro-peptide is processed, that extension is liberated as a 24-amino-acid peptide. Research-grade “MGF” is that synthetic 24-mer, not the full pro-hormone. The rodent equivalent is IGF-1Eb, which is a frequent source of confusion when comparing rodent and human papers.

Key identifiers for the synthetic E-domain peptide:

• Compound names: MGF, mechano growth factor, IGF-1Ec E-domain peptide, MGF E-peptide; PEG-MGF for the pegylated conjugate
• Sequence (one-letter): YQPPSTNKNTKSQRRKGSTFEERK
• Sequence (three-letter): Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-NH₂
• Length: 24 amino acid residues, typically supplied as the C-terminal amide
• Molecular formula (core peptide, amide form): C₁₂₁H₂₀₀N₄₂O₃₉
• Molecular weight (core peptide): approximately 2,867 g/mol
• Parent gene / UniProt: IGF1 / P05019 (IGF1_HUMAN), E-domain region

PEG-MGF has no single stable molecular weight or CAS number, and that is a characterization problem worth stating plainly. The core peptide is well defined; the PEG moiety is not standardized across suppliers. Conjugates in the research market are built on PEG chains ranging from roughly 2 kDa to 20 kDa or more, so the total mass of a PEG-MGF preparation depends entirely on the polymer used and on whether conjugation is mono- or multi-site. A vendor listing “PEG-MGF” without specifying the PEG size, the conjugation chemistry, and the attachment site has not actually told you what is in the vial. Two preparations sold under the same name can differ substantially in mass, in the fraction of unconjugated peptide present, and in behavior in an assay.

The peptide itself is notably basic — the Arg-Arg-Lys cluster near the center of the sequence gives it a strong positive charge at physiological pH — and that charge is central to the mechanistic hypotheses discussed below.

Section 2 — Mechanism

Everything here is described at the pathway and receptor level, and the honest summary is that the mechanism of the isolated E-peptide remains contested.

The splicing switch. The best-established part of the story is upstream of the peptide itself. Mechanical loading and local tissue damage shift IGF-1 pre-mRNA splicing toward the exon-5-containing isoform, producing a transient rise in IGF-1Ec/IGF-1Eb transcript before the systemic IGF-1Ea isoform rises. This temporal separation — a local, damage-associated transcript preceding the general growth transcript — is what led the original investigators to describe MGF as a mechanically triggered local factor rather than an endocrine one.

Proposed division of labor. The dominant hypothesis in the muscle literature is that the two cleavage products of pro-IGF-1Ec act sequentially: the E-peptide has been studied for expansion of the myoblast and satellite-cell pool through proliferation, while mature IGF-1 has been studied for driving differentiation and fusion through the IGF-1 receptor and the PI3K/Akt and MAPK cascades. In cultured myoblasts, the E-peptide has been reported to increase proliferation while suppressing markers of differentiation, with associated down-regulation of myogenic transcription factors including MyoD and myogenin in some model systems.

Receptor question. The E-peptide does not carry the IGF-1 receptor binding surface, and no dedicated MGF receptor has been cloned. Proposed explanations include a distinct, unidentified receptor; charge-driven interaction with cell-surface heparan sulfate proteoglycans and the extracellular matrix; and nuclear or nucleolar localization following internalization, which has been reported in several cell types. Separate work has described the C-terminal peptide acting independently of the rest of the molecule in a neuronal ischemia model, which is the main line of evidence for autonomous activity outside muscle.

Why pegylation. The unmodified 24-mer is a small, highly charged, protease-accessible peptide with a very short half-life in biological media. Conjugating PEG increases hydrodynamic radius, shields cleavage sites, and slows clearance. Pegylation is a pharmacokinetic modification, not a pharmacodynamic one — it is studied for extending exposure time in an experimental system, and can also reduce receptor-level potency by steric hindrance. Both effects should be assumed until measured in the specific system under study.

Section 3 — Preclinical Research Data

The MGF dataset divides into three groups, and the third is the reason the compound is interesting rather than settled.

Expression studies. The most reproducible findings concern the splicing response itself. Rodent muscle subjected to mechanical damage or to a myotoxic agent shows a rise in the exon-5-containing IGF-1 transcript that precedes satellite-cell activation, with the systemic IGF-1Ea isoform rising later. These are transcript-level measurements in animal tissue and they are the sturdiest part of the record.

Positive cell-culture and animal studies. Synthetic E-peptide has been reported to increase myoblast proliferation while restraining differentiation, and to increase the pool of muscle progenitor cells in human primary cultures from donors across a range of ages, with a reported increase in fusion potential in those cultures. Rodent work using local delivery of MGF-expressing constructs has reported increases in muscle mass over a period of weeks, and independent groups have reported proliferative and differentiation-suppressing effects in porcine satellite cells. Outside muscle, the synthetic C-terminal peptide has been reported to protect vulnerable neurons in a gerbil model of transient brain ischemia, and to modulate apoptosis and inflammatory signaling in fibroblast-like synoviocytes in vitro.

The negative replication. In 2014, a group working with C2C12 cells and primary human skeletal-muscle myoblasts reported that synthetic MGF peptide at concentrations up to 500 ng/mL failed to increase proliferation, while mature IGF-1 and full-length IGF-1Eb produced a clear proliferative response in the same cells. This is a direct challenge to the central in-vitro claim, and it has not been fully reconciled. Proposed explanations include differences in peptide synthesis quality and purity, C-terminal amidation state, serum conditions, and the passage history of the cell lines used. Any researcher designing work with this compound should read that paper alongside the positive reports rather than after them. The state of the evidence is genuinely unsettled, and a research guide that presented it otherwise would be misrepresenting the literature.

Section 4 — Published Literature

The following are real, published papers. Researchers should consult the primary sources directly.

• Yang S, Alnaqeeb M, Simpson H, Goldspink G (1996). “Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch.” Journal of Muscle Research and Cell Motility 17(4):487–495. The original identification of the stretch-associated splice variant.
• Yang SY, Goldspink G (2002). “Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation.” FEBS Letters 522(1–3):156–160. The basis of the proliferation-versus-differentiation hypothesis.
• Hill M, Goldspink G (2003). “Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage.” Journal of Physiology 549(Pt 2):409–418.
• Hill M, Wernig A, Goldspink G (2003). “Muscle satellite (stem) cell activation during local tissue injury and repair.” Journal of Anatomy 203(1):89–99.
• Dłużniewska J, et al. (2005). “A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia.” FASEB Journal 19(13):1896–1898.
• Matheny RW Jr, Nindl BC, Adamo ML (2010). “Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration.” Endocrinology 151(3):865–875. The most useful critical overview of the field.
• Kandalla PK, Goldspink G, Butler-Browne G, Mouly V (2011). “Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.” Mechanisms of Ageing and Development 132(4):154–162.
• Fornaro M, et al. (2014). “Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.” American Journal of Physiology — Endocrinology and Metabolism 306(2):E150–E156. The principal negative report.

Read together, these span the discovery of the splice variant, the mechanistic hypothesis built on it, the strongest supporting cell and animal work, and the replication failure that keeps the question open.

Section 5 — Research Applications

In laboratory settings, synthetic MGF and PEG-MGF appear chiefly as tool reagents in myogenesis research. Reported in-vitro applications include treatment of C2C12 myoblasts and primary human muscle progenitor cells in proliferation and differentiation assays; use as a comparator against mature IGF-1 and full-length pro-IGF-1 isoforms to test the sequential-action hypothesis; investigation of nuclear and nucleolar localization by immunocytochemistry; and use in neuronal and synoviocyte culture models where autonomous E-peptide activity has been proposed. Pegylated material is used where extended exposure is needed in longer culture experiments or in animal pharmacokinetic work.

Several experimental variables deserve explicit documentation. The amidation state of the C-terminus should be recorded, since amide and free-acid preparations are not identical materials. Serum conditions matter, because IGF-binding proteins in serum interact with IGF-family peptides and can confound comparisons between the E-peptide and mature IGF-1. Peptide purity matters more than usual here: with a contested effect size, a truncated or deletion-sequence impurity is a plausible source of discordant results between laboratories.

Handling follows standard practice for a basic, hygroscopic lyophilized peptide — storage of the lyophilized powder at −20°C, protection from light and moisture, reconstitution in an appropriate sterile buffer, and avoidance of repeated freeze-thaw cycles. Stock concentrations should be verified rather than assumed, particularly for pegylated material where the peptide represents only a fraction of the total mass. A milligram of PEG-MGF is not a milligram of peptide, and calculating molarity from total vial mass without accounting for the PEG contribution is a common and consequential error.

Section 6 — How to Evaluate a Source

For this compound, the certificate of analysis carries more weight than it does for most, because the underlying literature is contested and material quality is one of the leading explanations for that inconsistency. When evaluating any MGF or PEG-MGF source, a researcher should confirm:

• Identity by mass spectrometry (LC-MS), with the observed mass matching the expected 24-mer at approximately 2,867 g/mol for the amide form — and, for pegylated material, a stated PEG size, conjugation chemistry, and attachment site rather than the bare label “PEG-MGF.”
• Purity by HPLC, expressed as a percentage with the chromatogram shown, so that truncation and deletion sequences are visible rather than merely summarized.
• Peptide content, distinct from purity, which quantifies how much of the vial mass is actually peptide as opposed to counterion, residual water, and — in conjugates — polymer.
• Endotoxin by USP <85> LAL, which is essential for any cell-based work, since endotoxin independently activates inflammatory signaling and will confound proliferation assays.
• Heavy metals by ICP-MS.
• Lot-specificity: the COA should match the exact batch shipped, be dated, and name the accredited laboratory that performed the testing.

Market pricing for research-grade MGF and PEG-MGF is typically quoted per 2 mg or 5 mg lyophilized vial, and the spread between suppliers is wide. That spread reflects synthesis quality, purification depth, and — for conjugates — whether pegylation was characterized at all. Price is not a proxy for any of it. A cheap vial with no chromatogram and no stated PEG specification is not a discount on the same product; it is a different and less defined material.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

Founding batches are documented end to end, with the full analytical data file available per lot. You can review current documentation in the COA library, read the underlying methodology on the verification standard page, or browse the full catalog in the shop.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.